Avara Pharmaceuticals's latest lobbying report covers Q1 2026, at under $5,000. Its first report covers Q4 2025; the issues it reports most are Health Issues.

Avara Pharmaceuticals

Latest quarter: No record; Q2 2026 · 0 reports
Last 12 months: $60K; Last 3 quarters
vs last quarter: No record; Q2 2026 against the quarter before
First report: Q4 2025; The first quarter a report named it

Lobbying by quarter

Policy issues the reports name

Health issues2 reports

A report that names several issues counts once for each.

Who was lobbied

HOUSE OF REPRESENTATIVES2 reports
SENATE2 reports

Firms it paid

Firm
The Vogel Group	$60K	2 quarters

Former officials lobbying for it

	Former position	Firm
ALEXANDER NICHOLAS VOGEL sr	Former Chief Counsel, Senate Majority Leader Bill Frist	The Vogel Group	Q1 2026

Lobbying reports

	Filed by		Issues
04/20for Q1	The Vogel Group	Under $5,000	Health issues
01/20for Q4 2025	The Vogel Group	$60K	Health issues
25/11/26for Q4 2025	The Vogel Group	Under $5,000	Health issues